{"title":"Nisin ZP Combined with Limited Chemotherapy in Oropharyngeal Squamous Cell Carcinoma: A Case Report.","authors":"Qianlin Ye, Aimin He, Yeping Wu, Yvonne L Kapila","doi":"10.26502/acmcr.96550671","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This case report describes and discusses the therapeutic potential of nisin ZP as adjunctive therapy in patients with oral squamous cell carcinoma (OSCC).</p><p><strong>Case report: </strong>A 43-year-old Asian male with OSCC initiated treatment with Paclitaxel and Cisplatin chemotherapy. Nisin ZP was administrated during and after the chemotherapy.</p><p><strong>Results: </strong>The patient experienced symptom relief and significant tumor regression following administration of nisin ZP.</p><p><strong>Conclusion: </strong>Nisin ZP shows promising potential as an adjunctive therapy for OSCC, offering symptom relief and contributing to tumor size reduction.</p>","PeriodicalId":72280,"journal":{"name":"Archives of clinical and medical case reports","volume":"8 3","pages":"112-115"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12945336/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of clinical and medical case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/acmcr.96550671","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This case report describes and discusses the therapeutic potential of nisin ZP as adjunctive therapy in patients with oral squamous cell carcinoma (OSCC).
Case report: A 43-year-old Asian male with OSCC initiated treatment with Paclitaxel and Cisplatin chemotherapy. Nisin ZP was administrated during and after the chemotherapy.
Results: The patient experienced symptom relief and significant tumor regression following administration of nisin ZP.
Conclusion: Nisin ZP shows promising potential as an adjunctive therapy for OSCC, offering symptom relief and contributing to tumor size reduction.